nach oben

Erschienen in:

20.05.2019 | Original Article

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

verfasst von: Jérôme Cornillon, Elisabeth Daguenet, Jacques-Olivier Bay, Adrien Chauchet, Gilles Salles, Nathalie Contentin, Emmanuelle Nicolas-Virelizier, Mélanie Mercier, Nicolas Vallet, Magda Alexis, Marie-Lorraine Chrétien, Thomas Cluzeau, Anne Huynh, Chantal Himberlin, Véronique Dorvaux, Sandy Amorim, Caroline Lejeune, Régis Peffault de Latour, Emmanuel Gyan

Erschienen in: Annals of Hematology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

High-dose chemotherapy before autologous transplantation is a therapeutic option as consolidation in primary or relapsed lymphoma. Even if BEAM conditioning is generally used, alternative conditioning regimens have been published. The purpose of this study was to assess the outcome of 177 adult patients with lymphoma whose conditioning treatment included a BAM (busulfan, aracytine, and melphalan) regimen. With a median follow-up of 17.4 months, 2-year estimates of overall survival and progression-free survival for the entire group were 87% and 70.5%, respectively. Mucositis was the main reported complications and infectious episodes were described in 80.2% of patients. According to multivariate analysis, high performance status and age at diagnosis were adverse factors for survival and increased the risk of disease relapse and death. Despite its limitations, this retrospective study suggests that BAM combination is a valid conditioning regimen in lymphoma patients, with an acceptable rate of toxicity.

Nur mit Berechtigung zugänglich

Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545. https://doi.org/10.1056/NEJM199512073332305 CrossRefPubMed

Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 13:588–595. https://doi.org/10.1200/JCO.1995.13.3.588 CrossRef

Andre M, Henry-Amar M, Pico JL et al (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol 17(1):222–229. https://doi.org/10.1200/JCO.1999.17.1.222 CrossRefPubMed

Fernandez HF, Escalón MP, Pereira D, Lazarus HM (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 40:505–513. https://doi.org/10.1038/sj.bmt.1705744 CrossRefPubMed

Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, Artz AS, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson RF, Saber W, McCarthy PL, Pasquini MC (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1046–1053. https://doi.org/10.1016/j.bbmt.2015.02.005 CrossRefPubMedPubMedCentral

Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E, GEL/TAMO Spanish Cooperative Group (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant 27:405–412. https://doi.org/10.1038/sj.bmt.1702795 CrossRefPubMed

Jo J-C, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2007) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87:43–48. https://doi.org/10.1007/s00277-007-0360-0 CrossRefPubMed

Damaj G, cornillon J, Bouabdallah K et al (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Nature Publishing Group, London, pp 1–9. https://doi.org/10.1038/bmt.2016.340 CrossRef

Isidori A, Christofides A, Visani G (2016) Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 57:2499–2509. https://doi.org/10.1016/S0140-6736(15)60165-9 CrossRefPubMed

10.

Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, André M, Lepage E, Ferme C, SFGM/GELA Study Group (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA study group. Ann Oncol 10:1485–1488CrossRefPubMed

11.

Jonkhoff AR, De Kreuk AM, Franschman G et al (2002) Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin’s lymphoma. Br J Haematol 118:90–100CrossRefPubMed

12.

Puig N, de la Rubia J, Remigia MJ et al (2009) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 47:1488–1494. https://doi.org/10.1038/sj.bmt.1704110 CrossRef

13.

Sharma A, Kayal S, Iqbal S, Malik PS, Raina V (2013) Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus 2:489. https://doi.org/10.1186/2193-1801-2-489 CrossRefPubMedPubMedCentral

14.

Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35:183–187. https://doi.org/10.1016/j.leukres.2010.07.016 CrossRefPubMed

15.

Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31:1662–1668. https://doi.org/10.1200/JCO.2012.45.9453 CrossRefPubMedPubMedCentral

16.

Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB (2013) Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 19:410–417. https://doi.org/10.1016/j.bbmt.2012.10.029 CrossRefPubMed

17.

Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, Miguel JFS (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20:451–458. https://doi.org/10.1038/sj.bmt.1700913 CrossRefPubMed

18.

Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave P, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 105:4215–4222. https://doi.org/10.1182/blood-2005-01-0035 CrossRefPubMedPubMedCentral

Titel: BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
verfasst von: Jérôme Cornillon
Elisabeth Daguenet
Jacques-Olivier Bay
Adrien Chauchet
Gilles Salles
Nathalie Contentin
Emmanuelle Nicolas-Virelizier
Mélanie Mercier
Nicolas Vallet
Magda Alexis
Marie-Lorraine Chrétien
Thomas Cluzeau
Anne Huynh
Chantal Himberlin
Véronique Dorvaux
Sandy Amorim
Caroline Lejeune
Régis Peffault de Latour
Emmanuel Gyan
Publikationsdatum: 20.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 8/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03704-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy

Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman’s disease

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life

Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin